This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Toxicity and interactions

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • included in the pooled clinical trial database of 3,082 patients treated with venlafaxine were 14 patients who had taken an overdose of venlafaxine - all 14 patients survived the overdose and recovered without sequelae. One patient ingested 2.75 grams of venlafaxine and did suffer two epileptiform convulsions and developed a prolonged QT interval

  • monoamine oxidase inhibitors are contraindicated with venlafaxine - it is advised that there is a 14-day washout period between stopping an MAOI and starting venlafaxine treatment. The 'Serotonin syndrome' may occur as a result of inadvertent consumption of venlafaxine and an MAOI

  • during clinical trials, discontinuation phenomena from venlafaxine were reported with abrupt discontinuation after daily doses of 150 mg per day or higher - these usually occurred within 2 days of significant dose reduction and generally resolved within 7 days of stopping treatment. The commonly reported phenomena were headache, nausea and dizziness (1)

Reference:

  • Prescribers' Journal (1999), 39 (4), 243-247.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.